IMNR - Immune Response Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMNR - Immune Response

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: FRANKIES who wrote (165)	11/17/1997 11:53:00 AM
From: Mark Chavez	Read Replies (1) of 1510

Bernie - it's a PDF file, you'll need Acrobat reader and appropriate browser. Here's the Lehman link for their stock research reports: lehman.com Quick summary: 11/11/97 price = $11 1/8, Rank (current) =3, price target = $10 * IMNR phase II results for rheumatoid arthritis vaccine (IR501), lower dose group (90 mg) show statistically significant 50% improvement in ACR criteria, higher dose group (300 mg) showed a 37% improvement which was not statistically significant. A IIb trial will begin in 4Q97. * Interim results from phase III study using Remune should be announced by May 1998 * A phase II program for psoriasis should commence by year end while a phase II in colon cancer is scheduled to begin by 1Q98. * The Gene Drug delivery program should enter the clinic this year while the Hep-B gene delivery program is a candidate for a partnership by year end. Please consult the document for details, hope this helps. Mark.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next